Vanda Pharmaceuticals Inc... (VNDA)
| Bid | 4.67 |
| Market Cap | 272.63M |
| Revenue (ttm) | 199.34M |
| Net Income (ttm) | -18.95M |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -14.17 |
| Forward PE | 22.12 |
| Analyst | Strong Buy |
| Ask | 5.34 |
| Volume | 250,108 |
| Avg. Volume (20D) | 630,185 |
| Open | 4.62 |
| Previous Close | 4.60 |
| Day's Range | 4.57 - 4.69 |
| 52-Week Range | 3.87 - 6.75 |
| Beta | 0.69 |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...
Analyst Forecast
According to 2 analyst ratings, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 252.94% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call TranscriptVanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid...
